Lexeo Therapeutics
LXEO
139 hedge funds and large institutions have $459M invested in Lexeo Therapeutics in 2026 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 58 increasing their positions, 38 reducing their positions, and 27 closing their positions.
548% more call options, than puts
Call options by funds: $389K | Put options by funds: $60K
53% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 38
4.7% more ownership
Funds ownership: 104.76% → 109.46% (+4.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 146 → 139 (-7)
22% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 27
40% less capital invested
Capital invested by funds: $759M → $459M (-$300M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
+$13.1M |
| 2 |
O
OrbiMed
New York
|
+$10.5M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$10.1M |
| 4 |
Goldman Sachs
New York
|
+$8.28M |
| 5 |
SSC
Spruce Street Capital
New York
|
+$5.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$10.1M |
| 2 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$7.16M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$6.13M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$4.43M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$4.25M |
LXEO Hedge Fund Activity: Q1 2026 in Review
139 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Lexeo Therapeutics (LXEO) for Q1 2026, worth a combined $459M — down 40% from $759M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of LXEO and 21 opened new positions — a net loss of 6 holders — while 38 trimmed existing stakes and 58 added.
The largest buyer was Affinity Asset Advisors, adding an estimated $13.1M. The largest seller was Avoro Capital Advisors, cutting an estimated $10.1M.
- 139 institutional investors held Lexeo Therapeutics (LXEO) as of Q1 2026, down from 146 in Q4 2025.
- Funds reported $459M of Lexeo Therapeutics stock for Q1 2026, down 40% quarter-over-quarter.
- 21 funds opened new Lexeo Therapeutics positions in Q1 2026 and 27 closed out, a net change of -6 holders.
- The largest Lexeo Therapeutics buyer in Q1 2026 was Affinity Asset Advisors, an estimated $13.1M added.
- The largest Lexeo Therapeutics seller in Q1 2026 was Avoro Capital Advisors, an estimated $10.1M sold.
Based on aggregated 13F filings for Q1 2026.